12:13 PM EDT, 04/04/2024 (MT Newswires) -- Boston Scientific ( BSX ) and Axonics ( AXNX ) received a second request from the US Federal Trade Commission regarding the regulatory agency's review of their proposed merger, Boston Scientific ( BSX ) disclosed Thursday.

The request for additional information will extend the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act until 30 days after both companies have substantially complied with the request.

Both companies will promptly respond to the FTC request and will continue to cooperate with the commission during the review process.

The companies now expect to close the merger in H2, subject to expiration or termination of the waiting period and satisfaction of other customary closing conditions.

Price: 68.83, Change: +0.70, Percent Change: +1.03